Historical Stock Chart
3 Months : From Oct 2019 to Jan 2020
Starting next year, Amgen Inc. will list Repatha for $5,850 a year for all insurers. It rolled out at that price last year, but still supplied the treatment at the original price of more than $14,000 in some cases. "Amgen Posts Stronger-than-Expected 3Q Results -- Earnings Review" at 16:18 p.m. ET, incorrectly stated that $5,850 was 60% lower than the current price.
(END) Dow Jones Newswires
October 29, 2019 18:36 ET (22:36 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.